MR-CHOP therapy (high dose MTX with R-CHOP) for primary CNS lymphoma.

MR-CHOP therapy (high dose MTX with R-CHOP) for primary CNS lymphoma. - MR-CHOP for PCNSL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020513

Enrollment

Registered

2016-01-09

Start date

2016-01-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary central nervous system lymphoma

Interventions

chemotherapy: MR-CHOP

MTX 2g/m2(day1), Rituximab 375mg/m2(day1), Cyclophosphamide 750mg/m2(day3), Doxorubicin 50mg/m2(day3), Vincristine 1.4mg/m2(day3), prednisolone 100mg(day1-5). 6 courses of MR-CHOP therapy followed by

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1, Primary CNS lymphoma; pathological confirmation of DLBCL or CD20 positive B malignant cells in cerebrospinal fluid. 2, adult as over 20 y/o 3, written informed consent

Exclusion criteria

Exclusion criteria: 1, extra CNS lesions 2, severe infectious disease 3, history of chemotherapy for lymphoma 4, HIV+, HTLV1+, HBs-Ag+ 5, judgement as inappropriate to inclusion to this study by physician

Design outcomes

Primary

Measure	Time frame
CR rate at 6 month after starting treatment	—

Secondary

Measure	Time frame
overall survival, adverse events	—

Countries

Japan

Contacts

Public ContactYasufumi Masaki

Kanazawa Medical University Department of hematology and Immunology

yasum@kanazawa-med.ac.jp076-218-8158

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026